Household & Personal Products
Compare Stocks
5 / 10Stock Comparison
SKIN vs NUS vs ELF vs IPAR vs COTY
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Household & Personal Products
Household & Personal Products
Household & Personal Products
SKIN vs NUS vs ELF vs IPAR vs COTY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Household & Personal Products | Household & Personal Products | Household & Personal Products | Household & Personal Products | Household & Personal Products |
| Market Cap | $118M | $345M | $3.44B | $3.01B | $2.20B |
| Revenue (TTM) | $296M | $1.49B | $1.52B | $1.49B | $5.79B |
| Net Income (TTM) | $-6M | $160M | $104M | $201M | $-536M |
| Gross Margin | 64.9% | 69.4% | 70.3% | 64.0% | 61.9% |
| Operating Margin | -3.6% | 4.4% | 11.1% | 18.0% | -0.3% |
| Forward P/E | — | 7.0x | 19.9x | 19.4x | 9.2x |
| Total Debt | $379M | $364M | $313M | $224M | $4.25B |
| Cash & Equiv. | $233M | $239M | $149M | $158M | $257M |
SKIN vs NUS vs ELF vs IPAR vs COTY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| The Beauty Health C… (SKIN) | 100 | 9.0 | -91.0% |
| Nu Skin Enterprises… (NUS) | 100 | 13.6 | -86.4% |
| e.l.f. Beauty, Inc. (ELF) | 100 | 284.2 | +184.2% |
| Inter Parfums, Inc. (IPAR) | 100 | 173.0 | +73.0% |
| Coty Inc. (COTY) | 100 | 34.8 | -65.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SKIN vs NUS vs ELF vs IPAR vs COTY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
NUS is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (7.0x vs 9.2x)
- +26.3% vs COTY's -45.3%
ELF ranks third and is worth considering specifically for growth exposure and valuation efficiency.
- Rev growth 28.3%, EPS growth -13.1%, 3Y rev CAGR 49.6%
- PEG 0.49 vs IPAR's 0.57
- 28.3% revenue growth vs NUS's -14.3%
IPAR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.54, yield 3.4%
- 255.2% 10Y total return vs ELF's 133.1%
- Lower volatility, beta 0.54, Low D/E 20.3%, current ratio 2.99x
- Beta 0.54, yield 3.4%, current ratio 2.99x
Among these 5 stocks, COTY doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.3% revenue growth vs NUS's -14.3% | |
| Value | Lower P/E (7.0x vs 9.2x) | |
| Quality / Margins | 13.5% margin vs COTY's -9.3% | |
| Stability / Safety | Beta 0.54 vs ELF's 2.36, lower leverage | |
| Dividends | 3.4% yield, 5-year raise streak, vs NUS's 3.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +26.3% vs COTY's -45.3% | |
| Efficiency (ROA) | 12.9% ROA vs COTY's -4.7%, ROIC 18.6% vs 2.3% |
SKIN vs NUS vs ELF vs IPAR vs COTY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SKIN vs NUS vs ELF vs IPAR vs COTY — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IPAR leads in 3 of 6 categories
ELF leads 2 • NUS leads 1 • SKIN leads 0 • COTY leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ELF leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
COTY is the larger business by revenue, generating $5.8B annually — 19.6x SKIN's $296M. IPAR is the more profitable business, keeping 13.5% of every revenue dollar as net income compared to COTY's -9.3%. On growth, ELF holds the edge at +37.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $296M | $1.5B | $1.5B | $1.5B | $5.8B |
| EBITDAEarnings before interest/tax | $9M | $118M | $235M | $291M | $314M |
| Net IncomeAfter-tax profit | -$6M | $160M | $104M | $201M | -$536M |
| Free Cash FlowCash after capex | $29M | $46M | $215M | $199M | $311M |
| Gross MarginGross profit ÷ Revenue | +64.9% | +69.4% | +70.3% | +64.0% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -3.6% | +4.4% | +11.1% | +18.0% | -0.3% |
| Net MarginNet income ÷ Revenue | -2.0% | +10.8% | +6.8% | +13.5% | -9.3% |
| FCF MarginFCF ÷ Revenue | +9.8% | +3.1% | +14.1% | +13.3% | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -6.7% | -16.9% | +37.8% | +1.8% | -1.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.0% | +139.7% | +116.7% | +2.3% | 0.0% |
Valuation Metrics
NUS leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 2.2x trailing earnings, NUS trades at a 93% valuation discount to ELF's 32.2x P/E. Adjusting for growth (PEG ratio), IPAR offers better value at 0.53x vs ELF's 0.79x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $118M | $345M | $3.4B | $3.0B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $264M | $471M | $3.6B | $3.1B | $6.2B |
| Trailing P/EPrice ÷ TTM EPS | -5.69x | 2.21x | 32.18x | 17.93x | -5.68x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.02x | 19.89x | 19.38x | 9.16x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.79x | 0.53x | — |
| EV / EBITDAEnterprise value multiple | 7331.15x | 3.29x | 17.85x | 11.33x | 9.36x |
| Price / SalesMarket cap ÷ Revenue | 0.39x | 0.23x | 2.62x | 2.02x | 0.37x |
| Price / BookPrice ÷ Book value/share | 2.02x | 0.44x | 4.74x | 2.74x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 3.17x | 7.50x | 29.86x | 15.80x | 7.93x |
Profitability & Efficiency
IPAR leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
NUS delivers a 20.4% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-14 for COTY. IPAR carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs IPAR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.4% | +20.4% | +8.9% | +18.4% | -14.1% |
| ROA (TTM)Return on assets | -1.2% | +11.3% | +4.5% | +12.9% | -4.7% |
| ROICReturn on invested capital | -6.8% | +7.3% | +13.5% | +18.6% | +2.3% |
| ROCEReturn on capital employed | -4.5% | +7.9% | +16.6% | +23.3% | +2.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 7 | 4 | 5 |
| Debt / EquityFinancial leverage | 6.20x | 0.45x | 0.41x | 0.20x | 1.07x |
| Net DebtTotal debt minus cash | $146M | $126M | $164M | $66M | $4.0B |
| Cash & Equiv.Liquid assets | $233M | $239M | $149M | $158M | $257M |
| Total DebtShort + long-term debt | $379M | $364M | $313M | $224M | $4.2B |
| Interest CoverageEBIT ÷ Interest expense | 0.81x | 15.14x | 6.48x | 50.40x | 0.23x |
Total Returns (Dividends Reinvested)
ELF leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ELF five years ago would be worth $20,505 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, NUS leads with a +26.3% total return vs COTY's -45.3%. The 3-year compound annual growth rate (CAGR) favors ELF at -11.8% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -35.0% | -26.9% | -20.6% | +10.9% | -19.6% |
| 1-Year ReturnPast 12 months | -35.9% | +26.3% | -7.2% | -18.8% | -45.3% |
| 3-Year ReturnCumulative with dividends | -91.7% | -77.1% | -31.4% | -32.7% | -79.4% |
| 5-Year ReturnCumulative with dividends | -92.9% | -80.0% | +105.0% | +41.9% | -75.8% |
| 10-Year ReturnCumulative with dividends | -91.6% | -48.8% | +133.1% | +255.2% | -83.0% |
| CAGR (3Y)Annualised 3-year return | -56.4% | -38.9% | -11.8% | -12.4% | -40.9% |
Risk & Volatility
IPAR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IPAR is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than ELF's 2.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IPAR currently trades 65.9% from its 52-week high vs SKIN's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.00x | 1.49x | 2.36x | 0.54x | 1.08x |
| 52-Week HighHighest price in past year | $2.69 | $14.62 | $150.99 | $142.61 | $5.34 |
| 52-Week LowLowest price in past year | $0.76 | $5.65 | $58.05 | $77.21 | $1.96 |
| % of 52W HighCurrent price vs 52-week peak | +33.8% | +48.0% | +40.9% | +65.9% | +46.8% |
| RSI (14)Momentum oscillator 0–100 | 52.1 | 46.4 | 42.3 | 55.9 | 70.6 |
| Avg Volume (50D)Average daily shares traded | 760K | 458K | 2.3M | 259K | 7.9M |
Analyst Outlook
IPAR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SKIN as "Hold", NUS as "Hold", ELF as "Buy", IPAR as "Hold", COTY as "Hold". Consensus price targets imply 60.4% upside for COTY (target: $4) vs 14.4% for IPAR (target: $108). For income investors, IPAR offers the higher dividend yield at 3.40% vs COTY's 0.61%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $1.30 | $11.00 | $95.17 | $107.50 | $4.01 |
| # AnalystsCovering analysts | 13 | 11 | 27 | 19 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | +3.4% | — | +3.4% | +0.6% |
| Dividend StreakConsecutive years of raises | — | 0 | 1 | 5 | 1 |
| Dividend / ShareAnnual DPS | — | $0.24 | — | $3.20 | $0.02 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.8% | +1.9% | +0.5% | 0.0% |
IPAR leads in 3 of 6 categories (Profitability & Efficiency, Risk & Volatility). ELF leads in 2 (Income & Cash Flow, Total Returns).
SKIN vs NUS vs ELF vs IPAR vs COTY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SKIN or NUS or ELF or IPAR or COTY a better buy right now?
For growth investors, e.
l. f. Beauty, Inc. (ELF) is the stronger pick with 28. 3% revenue growth year-over-year, versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). Nu Skin Enterprises, Inc. (NUS) offers the better valuation at 2. 2x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate e. l. f. Beauty, Inc. (ELF) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SKIN or NUS or ELF or IPAR or COTY?
On trailing P/E, Nu Skin Enterprises, Inc.
(NUS) is the cheapest at 2. 2x versus e. l. f. Beauty, Inc. at 32. 2x. On forward P/E, Nu Skin Enterprises, Inc. is actually cheaper at 7. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: e. l. f. Beauty, Inc. wins at 0. 49x versus Inter Parfums, Inc. 's 0. 57x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SKIN or NUS or ELF or IPAR or COTY?
Over the past 5 years, e.
l. f. Beauty, Inc. (ELF) delivered a total return of +105. 0%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: IPAR returned +255. 2% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SKIN or NUS or ELF or IPAR or COTY?
By beta (market sensitivity over 5 years), Inter Parfums, Inc.
(IPAR) is the lower-risk stock at 0. 54β versus e. l. f. Beauty, Inc. 's 2. 36β — meaning ELF is approximately 334% more volatile than IPAR relative to the S&P 500. On balance sheet safety, Inter Parfums, Inc. (IPAR) carries a lower debt/equity ratio of 20% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SKIN or NUS or ELF or IPAR or COTY?
By revenue growth (latest reported year), e.
l. f. Beauty, Inc. (ELF) is pulling ahead at 28. 3% versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). On earnings-per-share growth, the picture is similar: Nu Skin Enterprises, Inc. grew EPS 207. 8% year-over-year, compared to -609. 8% for Coty Inc.. Over a 3-year CAGR, ELF leads at 49. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SKIN or NUS or ELF or IPAR or COTY?
Inter Parfums, Inc.
(IPAR) is the more profitable company, earning 11. 3% net margin versus -6. 2% for Coty Inc. — meaning it keeps 11. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IPAR leads at 18. 2% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — ELF leads at 71. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SKIN or NUS or ELF or IPAR or COTY more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, e. l. f. Beauty, Inc. (ELF) is the more undervalued stock at a PEG of 0. 49x versus Inter Parfums, Inc. 's 0. 57x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Nu Skin Enterprises, Inc. (NUS) trades at 7. 0x forward P/E versus 19. 9x for e. l. f. Beauty, Inc. — 12. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COTY: 60. 4% to $4. 01.
08Which pays a better dividend — SKIN or NUS or ELF or IPAR or COTY?
In this comparison, IPAR (3.
4% yield), NUS (3. 4% yield), COTY (0. 6% yield) pay a dividend. SKIN, ELF do not pay a meaningful dividend and should not be held primarily for income.
09Is SKIN or NUS or ELF or IPAR or COTY better for a retirement portfolio?
For long-horizon retirement investors, Inter Parfums, Inc.
(IPAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 3. 4% yield, +255. 2% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IPAR: +255. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SKIN and NUS and ELF and IPAR and COTY?
Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SKIN is a small-cap quality compounder stock; NUS is a small-cap deep-value stock; ELF is a small-cap high-growth stock; IPAR is a small-cap deep-value stock; COTY is a small-cap quality compounder stock. NUS, IPAR, COTY pay a dividend while SKIN, ELF do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.